E
Nuo Therapeutics, Inc.
AURX
$1.58
-$0.02-1.25%
E
Sell
3/14/2023Downgrade
Nuo Therapeutics, Inc. (AURX) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index and total return index.
Nuo Therapeutics, Inc. (AURX) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index and total return index.
D
Sell
2/9/2023Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D from E+ on 02/09/2023.
Nuo Therapeutics, Inc. (AURX) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Nuo Therapeutics, Inc. (AURX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
Nuo Therapeutics, Inc. (AURX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
D
Sell
1/27/2023Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D from D- on 1/27/2023 due to an increase in the valuation index.
Nuo Therapeutics, Inc. (AURX) was upgraded to D from D- on 1/27/2023 due to an increase in the valuation index.
D
Sell
11/10/2022Downgrade
Nuo Therapeutics, Inc. (AURX) was downgraded to D- from D on 11/10/2022 due to a substantial decline in the growth index, valuation index and efficiency index. Total capital declined 10.49% from $3.91M to $3.5M.
Nuo Therapeutics, Inc. (AURX) was downgraded to D- from D on 11/10/2022 due to a substantial decline in the growth index, valuation index and efficiency index. Total capital declined 10.49% from $3.91M to $3.5M.
D
Sell
8/20/2019Downgrade
Nuo Therapeutics, Inc. (AURX) was downgraded to D from D+ on 8/20/2019 due to a significant decline in the efficiency index, total return index and solvency index. Total capital declined 110.61% from -$380.9 to -$802.2, the quick ratio declined from 0.2 to 0.01, and debt to equity increased from -0.46 to -0.33.
Nuo Therapeutics, Inc. (AURX) was downgraded to D from D+ on 8/20/2019 due to a significant decline in the efficiency index, total return index and solvency index. Total capital declined 110.61% from -$380.9 to -$802.2, the quick ratio declined from 0.2 to 0.01, and debt to equity increased from -0.46 to -0.33.
D
Sell
5/21/2019Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D+ from D on 5/21/2019 due to a significant increase in the efficiency index.
Nuo Therapeutics, Inc. (AURX) was upgraded to D+ from D on 5/21/2019 due to a significant increase in the efficiency index.
D
Sell
4/18/2019Downgrade
Nuo Therapeutics, Inc. (AURX) was downgraded to D from D+ on 4/18/2019 due to a major decline in the efficiency index, solvency index and valuation index.
Nuo Therapeutics, Inc. (AURX) was downgraded to D from D+ on 4/18/2019 due to a major decline in the efficiency index, solvency index and valuation index.
D
Sell
4/15/2019Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D+ from D on 4/15/2019 due to an increase in the total return index.
Nuo Therapeutics, Inc. (AURX) was upgraded to D+ from D on 4/15/2019 due to an increase in the total return index.
D
Sell
3/29/2019Downgrade
Nuo Therapeutics, Inc. (AURX) was downgraded to D from D+ on 3/29/2019 due to a decline in the total return index.
Nuo Therapeutics, Inc. (AURX) was downgraded to D from D+ on 3/29/2019 due to a decline in the total return index.
D
Sell
3/12/2019Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D+ from D on 3/12/2019 due to a major increase in the total return index, volatility index and growth index. Total revenue increased 88.21% from $138.3 to $260.3, and EBIT increased 29.33% from -$582.7 to -$411.8.
Nuo Therapeutics, Inc. (AURX) was upgraded to D+ from D on 3/12/2019 due to a major increase in the total return index, volatility index and growth index. Total revenue increased 88.21% from $138.3 to $260.3, and EBIT increased 29.33% from -$582.7 to -$411.8.
D
Sell
5/25/2018Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D from D- on 5/25/2018 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 91.62% from -$8M to -$670.2.
Nuo Therapeutics, Inc. (AURX) was upgraded to D from D- on 5/25/2018 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 91.62% from -$8M to -$670.2.
D
Sell
2/20/2018Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D- from E+ on 2/20/2018 due to an increase in the growth index and volatility index.
Nuo Therapeutics, Inc. (AURX) was upgraded to D- from E+ on 2/20/2018 due to an increase in the growth index and volatility index.
E
Sell
11/15/2017Downgrade
Nuo Therapeutics, Inc. (AURX) was downgraded to E+ from D- on 11/15/2017 due to a decline in the solvency index, efficiency index and total return index.
Nuo Therapeutics, Inc. (AURX) was downgraded to E+ from D- on 11/15/2017 due to a decline in the solvency index, efficiency index and total return index.
D
Sell
11/1/2017Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to D- from E on 11/1/2017 due to an increase in the valuation index.
Nuo Therapeutics, Inc. (AURX) was upgraded to D- from E on 11/1/2017 due to an increase in the valuation index.
E
Sell
8/1/2017Upgraded
Nuo Therapeutics, Inc. (AURX) was upgraded to E from E- on 8/1/2017 due to a significant increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.2577 to -$0.1705, net income increased 31.86% from -$2.48M to -$1.69M, and EBIT increased 15.62% from -$2M to -$1.68M.
Nuo Therapeutics, Inc. (AURX) was upgraded to E from E- on 8/1/2017 due to a significant increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.2577 to -$0.1705, net income increased 31.86% from -$2.48M to -$1.69M, and EBIT increased 15.62% from -$2M to -$1.68M.
E
Sell
5/10/2017None
Nuo Therapeutics, Inc. (AURX) was downgraded to E- from U on 05/10/2017.
Nuo Therapeutics, Inc. (AURX) was downgraded to E- from U on 05/10/2017.
OTC PK
04/10/2025 12:57PM Eastern
Quotes delayed
